-- Scott Roberts
WEDNESDAY, Nov. 16 (HealthDay News) -- Jakafi (ruxolitinib) has
been approved by the U.S. Food and Drug Administration as the first
drug to treat myelofibrosis, a rare disease of the bone marrow, the
agency said Wednesday.
In cases of myelofibrosis, healthy bone marrow is replaced by
scar tissue, causing blood cells to be made in the liver, spleen
and other organs. Symptoms often include an enlarged spleen,
anemia, a decrease in white blood cells and platelets, fatigue,
abdominal discomfort, pain under the ribs, muscle and bone pain,
itching and night sweats, the FDA said in a news release.
Jakafi inhibits the actions of two enzymes that are involved in
regulating blood, the agency said. The drug was evaluated in
clinical studies involving 528 people, all of whom had an enlarged
Observed side effects included low blood platelet levels,
anemia, fatigue, diarrhea, shortness of breath, headache,
dizziness, nausea and confusion.
Jakafi was approved as an orphan drug, since myelofibrosis
affects fewer than 200,000 people in the United States, the FDA
The drug is produced by Incyte Corp., based in Wilmington,
The FDA has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.